B
Bull
Bull · 25%PVLA
$34.32
Scenario price
$151.580
+4.229 (+2.79%)At close
Loading chart…
- High
- 156.820
- Open
- 149.650
- VWAP
- 151.62
- Volume
- 342.96K
- Mkt Cap
- —
- Low
- 146.470
- Amount
- 52.00M
- EV/EBITDA, TTM
- 0.00
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
AI analysis of Palvella Therapeutics Inc (PVLA)
HoldPalvella Therapeutics is not a good buy right now due to its current price of $125.1, which is significantly below the analyst price targets of $240 and $246. However, the stock has a low RSI of 42.86, indicating it is nearing oversold territory, which could present a buying opportunity in the future. The main risk is the negative earnings trend, with a reported EPS of -1.52, missing estimates by $0.34, which raises concerns about profitability and investor confidence.
Valuation Metrics
The current forward P/E ratio for Palvella Therapeutics Inc (PVLA) is 0.00, compared to its 5-year average forward P/E of -12.97.
Alphio AI Price Scenarios for PVLA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PVLA
Events Timeline
News
9.510-29NewsfilterPalvella Therapeutics to Report Q3 2026 Financial Results on November 5
- 9.010-28Newsfilter
QTORIN™ Rapamycin Poised to be First FDA-Approved Therapy for Microcystic Lymphatic Malformations
- 9.010-15Newsfilter
Palvella Reports New Developments on QTORIN™ Therapy
- 1.010-13Newsfilter
Palvella Therapeutics to Participate in Healthcare Conference
- 8.510-12Newsfilter
Palvella Reports SELVA Study Findings on QTORIN™ Rapamycin
PVLA FAQ — answered by Alphio AI
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations. It operates in the Healthcare sector.
Palvella Therapeutics is not a good buy right now due to its current price of $125.1, which is significantly below the analyst price targets of $240 and $246. However, the stock has a low RSI of 42.86, indicating it is nearing oversold territory, which could present a buying opportunity in the future. The main risk is the negative earnings trend, with a reported EPS of -1.52, missing estimates by $0.34, which raises concerns about profitability and investor confidence.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.